【藥品庫存】 本藥品為臨時採購藥品，經院長核可後，限定特定科別、病人使用。

Multiple sclerosis, relapsing: Treatment of patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Fumaric Acid Derivative

Distribution: Vd: MMF: 53 to 73 L
Protein binding: MMF: 27% to 45%
Metabolism: Undergoes rapid and extensive presystemic hydrolysis by esterases to its active metabolite, monomethyl fumarate (MMF); MMF is further metabolized via the tricarboxylic acid (TCA) cycle. Major serum metabolites include: MMF, fumaric acid, citric acid, and glucose.
Half-life elimination: MMF: ~1 hour
Time to peak: 2 to 2.5 hours; delayed to 5.5 hours with food
Excretion: CO2 via exhalation (~60%); urine (16%; trace amounts as unchanged MMF), feces (1%)

Known hypersensitivity (eg, anaphylaxis, angioedema) to dimethyl fumarate or any component of the formulation

nformation related to the use of dimethyl fumarate in pregnancy is limited.

It is not known if dimethyl fumarate is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Cardiovascular: Flushing (40%)
Gastrointestinal: Abdominal pain (18%), diarrhea (14%), nausea (12%)
Infection: Infection (60%; similar to placebo)

Multiple sclerosis, relapsing: Oral: Initial: 120 mg twice daily; after 7 days, increase to the maintenance dose: 240 mg twice daily.

No dosage adjustment necessary

No dosage adjustment necessary